Journal of Substance Abuse Treatment
Volume 28, Issue 1 , Pages 49-55 , January 2005

The effectiveness of nicotine patch and nicotine lozenge in very heavy smokers

  • Saul Shiffman, Ph.D.

      Affiliations

    • Pinney Associates, Pittsburgh, PA, USA
    • University of Pittsburgh, Smoking Research Group, Pittsburgh, PA, USA
    • Corresponding Author InformationCorresponding author. Pinney Associates, 201 North Craig Street, Suite 320, Pittsburgh, PA 15213, USA. Tel.: +1 412 687 5677; fax: +1 412 687 4855
    • ,
  • Michael E. Di Marino, M.A.

      Affiliations

    • Pinney Associates, Bethesda, MD, USA
    • ,
  • Janine L. Pillitteri, Ph.D.

      Affiliations

    • Pinney Associates, Seattle, WA, USA

Received 31 May 2004 ,Revised 20 September 2004 ,Accepted 28 October 2004.

References 

  1. Benowitz NL. Nicotine replacement therapy. What has been accomplished—can we do better?. Drugs. 1993;45:157–170
  2. Blondal T, Gudmundsson LJ, Olafsdottir I, Gustavsson G, Westin A. Nicotine nasal spray with nicotine patch for smoking cessation: Randomised trial with six year follow up. British Medical Journal. 1999;318:285–289
  3. Burns, D. M. (2000). Smoking cessation: recent indicators of what’s working at a population level. Bethesda, MD, U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute, NIH Pub. No. 00–4892. Population Based Smoking Cessation: Proceedings of a Conference on What Works to Influence Cessation in the General Population. Smoking and Tobacco Control Monograph No. 12.
  4. Choi JH, Dresler CM, Norton MR, Strahs KR. Pharmacokinetics of a nicotine polacrilex lozenge. Nicotine & Tobacco Research. 2003;5:635–644
  5. Cohen S, Lichtenstein E, Prochaska JO, Rossi JS, Gritz E, Clifford CR, et al. Debunking myths about self-quitting. American Psychologist. 1989;44:1355–1365
  6. Dale LC, Hurt RD, Offord KP, Lawson GM, Croghan IT, Schroeder DR. High-dose nicotine patch therapy. Percentage of replacement and smoking cessation. JAMA. 1995;274:1353–1358
  7. Doll R, Peto R, Wheatley K, Gray R, Sutherland I. Mortality in relation to smoking: 40 years’ observations on male British doctors. British Medical Journal. 1994;309:901–911
  8. Fagerström KO, Kunze M, Schoberberger R, Breslau N, Hughes JR, Hurt RD, et al. Nicotine dependence versus smoking prevalence: Comparisons among countries and categories of smokers. Tobacco Control. 1996;5:52–56
  9. Fagerström KO, Schneider NG, Lunell E. Effectiveness of nicotine patch and nicotine gum as individual versus combined treatments for tobacco withdrawal symptoms. Psychopharmacology. 1993;111:271–277
  10. Fant RV, Henningfield JE, Shiffman S, Strahs KR, Reitberg DP. A pharmacokinetic crossover study to compare the absorption characteristics of three transdermal nicotine patches. Pharmacology, Biochemistry & Behavior. 2000;67:479–482
  11. Fiore MC, Bailey WC, Cohen SJ, Faith Dorfman S, Goldstein MG, Gritz ER, et al. Treating Tobacco Use and Dependence. Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service; 2000;
  12. Fredrickson PA, Hurt RD, Lee GM, Wingender L, Croghan IT, Lauger G, et al. High dose transdermal nicotine therapy for heavy smokers: safety, tolerability and measurement of nicotine and cotinine levels. Psychopharmacology. 1995;122:215–222
  13. Goldstein MG. Pharmacotherapy for smoking cessation. In:  Abrams DB,  Niaura R,  Brown RA,  Emmons KM,  Goldstein MG,  Monti PM editor. The tobacco dependence treatment handbook: A guide to best practices. New York: The Guilford Press; 2003;p. 230–248
  14. Hajek P, West R, Foulds J, Nilsson F, Burrows S, Meadow A. Randomized comparative trial of nicotine polacrilex, a transdermal patch, nasal spray, and an inhaler. Archives of Internal Medicine. 1999;159:2033–2038
  15. Heatherton T, Kozlowski LT, Frecker R, Rickert W, Robinson J. Measuring the heaviness of smoking: Using self-reported time to the first cigarette of the day and number of cigarettes smoked per day. British Journal of Addiction. 1989;84:791–800
  16. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. British Journal of Addiction. 1991;86:1119–1127
  17. Herrera N, Franco R, Herrera L, Partidas A, Rolando R, Fagerström KO. Nicotine gum, 2 and 4 mg, for nicotine dependence. A double-blind placebo-controlled trial within a behavior modification support program. Chest. 1995;108:447–451
  18. Hughes JR. Combined psychological and nicotine gum treatment for smoking: A critical review. Journal of Substance Abuse. 1991;3:337–350
  19. Hughes JR, Giovino GA, Klevens RM, Fiore MC. Assessing the generalizability of smoking studies. Addiction. 1997;92:469–472
  20. Hughes JR, Lesmes GR, Hatsukami DK, Richmond RL, Lichtenstein E, Jorenby DE, et al. Are higher doses of nicotine replacement more effective for smoking cessation?. Nicotine & Tobacco Research. 1999;1:169–174
  21. Hurt RD, Dale LC, Fredrickson PA, Caldwell CC, Lee GA, Offord KP, et al. Nicotine patch therapy for smoking cessation combined with physician advice and nurse follow-up. One-year outcome and percentage of nicotine replacement. JAMA. 1994;271:595–600
  22. Hymowitz N, Cummings KM, Hyland A, Lynn WR, Pechacek TF, Hartwell TD. Predictors of smoking cessation in a cohort of adult smokers followed for five years. Tobacco Control. 1997;6:S57–S62
  23. Jorenby DE, Smith SS, Fiore MC, Hurt RD, Offord KP, Croghan IT, et al. Varying nicotine patch dose and type of smoking cessation counseling. JAMA. 1995;274:1347–1352
  24. Killen JD, Fortmann SP, Davis L, Strausberg L, Varady A. Do heavy smokers benefit from higher dose nicotine patch therapy?. Experimental and Clinical Psychopharmacology. 1999;7:226–233
  25. Kornitzer M, Boutsen M, Dramaix M, Thijs J, Gustavsson G. Combined use of nicotine patch and gum in smoking cessation: A placebo-controlled clinical trial. Preventive Medicine. 1995;24:41–47
  26. Lubin JH, Gail MH. On power and sample size for studying features of the relative odds of disease. American Journal of Epidemiology. 1990;131:552–566
  27. Lunell E, Molander L, Ekberg K, Wahren J. Site of nicotine absorption from a vapour inhaler—comparison with cigarette smoking. European Journal of Clinical Pharmacology. 2000;55:737–741
  28. Molander L, Lunell E, Andersson SB, Kuylenstierna F. Dose released and absolute bioavailability of nicotine from a nicotine vapor inhaler. Clinical Pharmacology and Therapeutics. 1996;59:394–400
  29. National Center for Health Statistics. National Health Interview Survey. Hyattsville, MD: Author; 2000;
  30. Payne TJ, Smith PO, McCracken LM, McSherry WC, Antony MM. Assessing nicotine dependence: A comparison of the Fagerström Tolerance Questionnaire (FTQ) with the Fagerström Test for Nicotine Dependence (FTND) in a clinical sample. Addictive Behaviors. 1994;19:307–317
  31. Puska P, Korhonen H, Vartiainen E, Urjanheimo E, Gustavsson G, Westin A. Combined use of nicotine patch and gum compared with gum alone in smoking cessation: a clinical trial in North Karelia. Tobacco Control. 1995;4:231–235
  32. Sachs DP. Effectiveness of the 4-mg dose of nicotine polacrilex for the initial treatment of high-dependent smokers. Archives of Internal Medicine. 1995;155:1973–1980
  33. Shiffman S, Shadell WG, Niaura R, Khayrallah M, Jorenby D, Ryan C, et al. Efficacy of acute administration of nicotine gum in relief of cue-provoked cigarette craving. Psychopharmacology (Berl.). 2002;166:343–350
  34. Shiffman S, Dresler CM, Hajek P, Gilburt SJ, Targett DA, Strahs KR. Efficacy of a nicotine lozenge for smoking cessation. Archives of Internal Medicine. 2002;162:1267–1276
  35. Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation. Cochrane Database Systematic Review, CD000146. 2002;
  36. Sweeney CT, Fant RV, Fagerström KO, McGovern JF, Henningfield JE. Combination nicotine replacement therapy for smoking cessation: rationale, efficacy and tolerability. CNS Drugs. 2001;15:453–467
  37. Transdermal Nicotine Study Group. Transdermal nicotine for smoking cessation. The Journal of the American Medical Association. 1991;266:3133–3138
  38. U.S. Department of Health and Human Services. The Health Consequences Of Smoking: Nicotine Addiction. A Report of the Surgeon General (DHHS Publication No. CDC 88–8406). Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, Center for Health Promotion and Education, Office on Smoking and Health; Washington, DC; 1988;
  39. U.S. Department of Health and Human Services. The Health Benefits of Smoking Cessation. A Report of the Surgeon General (DHHS Publication No. CDC 90–8416). Rockville MD: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 1990;
  40. U.S. Department of Health and Human Services. Reducing Tobacco Use: A Report of the Surgeon General. Atlanta, Georgia: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2000;
  41. World Health Organization. Making a difference. World Health Report Geneva, Switzerland: WHO; 1999;

PII: S0740-5472(04)00127-8

doi: 10.1016/j.jsat.2004.10.006

Journal of Substance Abuse Treatment
Volume 28, Issue 1 , Pages 49-55 , January 2005

Article Tools